Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former…